Literature DB >> 26318819

LNA aptamer based multi-modal, Fe3O4-saturated lactoferrin (Fe3O4-bLf) nanocarriers for triple positive (EpCAM, CD133, CD44) colon tumor targeting and NIR, MRI and CT imaging.

Kislay Roy1, Rupinder K Kanwar1, Jagat R Kanwar2.   

Abstract

This is the first ever attempt to combine anti-cancer therapeutic effects of emerging anticancer biodrug bovine lactoferrin (bLf), and multimodal imaging efficacy of Fe3O4 nanoparticles (NPs) together, as a saturated Fe3O4-bLf. For cancer stem cell specific uptake of nanocapsules/nanocarriers (NCs), Fe3O4-bLf was encapsulated in alginate enclosed chitosan coated calcium phosphate (AEC-CP) NCs targeted (Tar) with locked nucleic acid (LNA) modified aptamers against epithelial cell adhesion molecule (EpCAM) and nucleolin markers. The nanoformulation was fed orally to mice injected with triple positive (EpCAM, CD133, CD44) sorted colon cancer stem cells in the xenograft cancer stem cell mice model. The complete regression of tumor was observed in 70% of mice fed on non-targeted (NT) NCs, with 30% mice showing tumor recurrence after 30 days, while only 10% mice fed with Tar NCs showed tumor recurrence indicating a significantly higher survival rate. From tumor tissue analyses of 35 apoptotic markers, 55 angiogenesis markers, 40 cytokines, 15 stem cell markers and gene expression studies of important signaling molecules, it was revealed that the anti-cancer mechanism of Fe3O4-bLf was intervened through TRAIL, Fas, Fas-associated protein with death domain (FADD) mediated phosphorylation of p53, to induce activation of second mitochondria-derived activator of caspases (SMAC)/DIABLO (inhibiting survivin) and mitochondrial depolarization leading to release of cytochrome C. Induction of apoptosis was observed by inhibition of the Akt pathway and activation of cytokines released from monocytes/macrophages and dendritic cells (interleukin (IL) 27, keratinocyte chemoattractant (KC)). On the other hand, the recurrence of tumor in AEC-CP-Fe3O4-bLf NCs fed mice mainly occurred due to activation of alternative pathways such as mitogen-activated protein kinases (MAPK)/extracellular signal-regulated kinases (ERK) and Wnt signaling leading to an increase in expression of survivin, survivin splice variant (survivin 2B) and other anti-apoptotic proteins Bad, Bcl-2 and XIAP. Apart from the promising anti-cancer efficacy and the exceptional tumor targeting ability observed by multimodal imaging using near-infrared (NIR) imaging, magnetic resonance imaging (MRI) and computerized tomographic (CT) techniques, these NCs also maintained the immunomodulatory benefits of bLf as they were able to increase the RBC, hemoglobin, iron calcium and zinc levels in mice.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bovine lactoferrin; Colon cancer stem cells; Fe(3)O(4); Locked nucleic acid (LNA); Nanotheranostic; Survivin

Mesh:

Substances:

Year:  2015        PMID: 26318819     DOI: 10.1016/j.biomaterials.2015.07.055

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  21 in total

1.  Controllable synthesis Fe3O4@POHABA core-shell nanostructure as high-performance recyclable bifunctional magnetic antimicrobial agent.

Authors:  Zhijia Zhang; Defeng Xing; Xin Zhao; Xiaojun Han
Journal:  Environ Sci Pollut Res Int       Date:  2017-06-28       Impact factor: 4.223

Review 2.  Trends in the Design and Development of Specific Aptamers Against Peptides and Proteins.

Authors:  Maryam Tabarzad; Marzieh Jafari
Journal:  Protein J       Date:  2016-04       Impact factor: 2.371

Review 3.  Aptamer-based targeted therapy.

Authors:  Guizhi Zhu; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2018-08-17       Impact factor: 15.470

Review 4.  Molecular Engineering of Functional Nucleic Acid Nanomaterials toward In Vivo Applications.

Authors:  JingJing Zhang; Tian Lan; Yi Lu
Journal:  Adv Healthc Mater       Date:  2019-02-06       Impact factor: 9.933

5.  Trends and Hotspots in Nanoparticles for the Targeted Delivery of Nucleic Acids: A Ten-Year Bibliometric Study.

Authors:  Yingzhao Huang; Qi Zhan; Chenzhou Wu; Nailin Liao; Zhou Jiang; Haoran Ding; Kunyu Wang; Yi Li
Journal:  Front Pharmacol       Date:  2022-05-04       Impact factor: 5.988

6.  The diagnosis of hepatic fibrosis by magnetic resonance and near-infrared imaging using dual-modality nanoparticles.

Authors:  Yunfang Li; Wenting Shang; Xiaoyuan Liang; Chaoting Zeng; Mingming Liu; Sudan Wang; Hongjun Li; Jie Tian
Journal:  RSC Adv       Date:  2018-02-12       Impact factor: 4.036

7.  In vivo fluorescence imaging of hepatocellular carcinoma using a novel GPC3-specific aptamer probe.

Authors:  Menglong Zhao; Lili Dong; Zhuang Liu; Shuohui Yang; Weizhong Wu; Jiang Lin
Journal:  Quant Imaging Med Surg       Date:  2018-03

8.  Superparamagnetic Fe3O4-PEG2K-FA@Ce6 Nanoprobes for in Vivo Dual-mode Imaging and Targeted Photodynamic Therapy.

Authors:  Ting Yin; Peng Huang; Guo Gao; Joseph G Shapter; Yulan Shen; Rongjin Sun; Caixia Yue; Chunlei Zhang; Yanlei Liu; Sui Zhou; Daxiang Cui
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

Review 9.  Chitosan nanoparticles as a promising tool in nanomedicine with particular emphasis on oncological treatment.

Authors:  Javad Sharifi-Rad; Cristina Quispe; Monica Butnariu; Lia Sanda Rotariu; Oksana Sytar; Simona Sestito; Simona Rapposelli; Muhammad Akram; Mehwish Iqbal; Akash Krishna; Nanjangud Venkatesh Anil Kumar; Susana S Braga; Susana M Cardoso; Karolina Jafernik; Halina Ekiert; Natália Cruz-Martins; Agnieszka Szopa; Marcelo Villagran; Lorena Mardones; Miquel Martorell; Anca Oana Docea; Daniela Calina
Journal:  Cancer Cell Int       Date:  2021-06-24       Impact factor: 5.722

Review 10.  Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy.

Authors:  Ewelina Piktel; Katarzyna Niemirowicz; Marzena Wątek; Tomasz Wollny; Piotr Deptuła; Robert Bucki
Journal:  J Nanobiotechnology       Date:  2016-05-26       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.